AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2357777
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (Group IV, 47 patients)
Trial: 26518
Drug: Proglumide (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumide (1200 mg per day for 28 days)
Trial: 26518
Drug: Cimetidine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1200 mg per day for 28 days)
Trial: 31568387
Drug: Plantar flexor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantar flexor strengthening associated with conventional physical therapy treatment
Trial: 31568387
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment (gait training, triceps surae muscle stretching, anterior tibial muscle strengthening, and motor sensory training)
Trial: 15625071
Drug: Gentamicin cream
RxNorm normalized name: gentamicin Topical Cream
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin cream
Trial: 19019257
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol or sterol ester (2 g)
Trial: 17682990
Drug: Zinc nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc nasal gel
Trial: 17682990
Drug: Zinc lozenges
RxNorm normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc lozenges or nasal spray
Trial: 16405839
Drug: Cytokines absorption
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokines absorption using sulfonated polyacrylonitrile hemofilter (AN69)
Trial: 12021824
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg caffeine
Trial: 6436891
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg caffeine
Trial: 8533175
Drug: Minimal exercise
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal exercise (twice weekly for three months)
Trial: 2080308
Drug: UDPG (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDPG (400 mg/im/die for 30 days)
Trial: 26446726
Drug: Home-based Parent-child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based Parent-child Interaction Therapy (PCIT)
Trial: 23875989
Drug: Proactive retention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive retention strategies including obtaining extensive contact information, building relationships with case managers and social workers, contacting jails and prisons, text messaging, e-mailing, messaging via social networking sites, identifying appointments via electronic medical record, and field outreach to treatment facilities, residences, and parks.
Trial: 19228214
Drug: Lidocaine inferior
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine inferior alveolar nerve block (IANB) with supplementary articaine buccal infiltration (2 mL of articaine 4% with epinephrine 1:100,000)
Trial: 19228214
Drug: Dummy buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy buccal injection
Trial: 17255371
Drug: Aprepitant (NK1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (NK1 antagonist)
Trial: 15371667
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) twice a day (BD group)
Trial: 7533998
Drug: Costimulatory stromal
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costimulatory stromal receptors identified in thymuses and TETs
Trial: 3065101
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bumetanide and spironolactone (group C, n = 12)
Trial: 26833454
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diacetyl boldine (DAB) serum at night and DAB/TGF‐β1 biomimetic oligopeptide‐68/sunscreen cream in the morning and at noon
Trial: 26833454
Drug: 2% and
RxNorm normalized name: clindamycin phosphate 12 mg in 1 g / tretinoin 0.25 mg in 1 g TOPICAL GEL [Clindamycin Phosphate 1.2% and Tretinoin 0.025%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% and 4% hydroquinone cream (HQ)
Trial: 24655469
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion protocol with a trigger of hemoglobin ≤ 6 g/dL; transfusion acceptable for hemoglobin 6-8 g/dL and only with evidence of end-organ ischemia for hemoglobin 8-10 g/dL.
Trial: 24655469
Drug: Transfusion for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion for hemoglobin 6-8 g/dL
Trial: 24655469
Drug: Transfusion for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion for hemoglobin 8-10 g/dL with evidence for end-organ ischemia
Trial: 23091107
Drug: Combination query
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination query
Trial: 20544311
Drug: Novel pharmacologic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel pharmacologic agents
Trial: 15811089
Drug: pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone 15 mg
Trial: 15811089
Drug: pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone 30 mg
Trial: 8566605
Drug: Perfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion with camostate (synthetic protease inhibitor)
Trial: 26486704
Drug: DEC 6
RxNorm normalized name: Zodryl DEC 60 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg
Trial: 15049459
Drug: DEC 6
RxNorm normalized name: Zodryl DEC 60 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 6 mg/kg + ALB 400 mg
Trial: 22747197
Drug: Cycle ergometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle ergometry training (30-min once weekly for 6 weeks)
Trial: 12971029
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg valdecoxib
Trial: 21661426
Drug: Tacrolimus (Tac)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (Tac) in double therapy (plus steroids)
Trial: 21661426
Drug: Cyclosporine microemulsion
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine microemulsion (CyA‐me) in triple therapy (plus steroids and azathioprine)
Trial: 14693085
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment groups vs control
Trial: 2849682
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (18 g/day)
Trial: 31506877
Drug: Lung protective
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung protective ventilation (LPV) with a tidal volume of 6 ml/IBW and PEEP of 10 cm H2O
Trial: 31506877
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (CV) with a tidal volume of 10 ml/IBW and PEEP of 4 cm H2O
Trial: 29231549
Drug: Acupoint transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.2 group, 50 cases)
Trial: 29231549
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous general anesthesia (No.1 group, 48 cases)
Trial: 29231549
Drug: Acupoint transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.3 group, 48 cases)
Trial: 23549132
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (control)
Trial: 21450069
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity screening (alone or in combination with diet)
Trial: 18505968
Drug: FEC-P (fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC-P (fluorouracil, epirubicin, cyclophosphamide followed by weekly paclitaxel)
Trial: 17160915
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg/day and 8 mg/day
Trial: 10764700
Drug: 100 U
RxNorm normalized name: vitamin E 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 U Botulinum toxin (initial injection)
Trial: 10764700
Drug: 100 U
RxNorm normalized name: vitamin E 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 U Botulinum toxin (second injection after 30 days)
Trial: 8842654
Drug: Xylitol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (0.25 g kg‐1 h‐1)
Trial: 8842654
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (0.5 g h‐1)
Trial: 1569343
Drug: Acid treatment
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Skin Laundry. Clean Slate Exfoliating 2 Salicylic Acid Treatment Gel Cleanser Cleanse Exfoliate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid treatment of plasma
Trial: 2411876
Drug: No speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No speech therapy
Trial: 24401754
Drug: 600 000IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 000IU single intramuscular injection
Trial: 23140417
Drug: Menaquinone-4 (MK-4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone-4 (MK-4) 420 μg (945 nmol) single dose
Trial: 23140417
Drug: Menaquinone-7 (MK-7)
RxNorm normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone-7 (MK-7) 420 μg (647 nmol) single dose
Trial: 23140417
Drug: Menaquinone-4 (MK-4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone-4 (MK-4) 60 μg (135 nmol) consecutive administration for 7 days
Trial: 23140417
Drug: Menaquinone-7 (MK-7)
RxNorm normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone-7 (MK-7) 60 μg (92 nmol) consecutive administration for 7 days
Trial: 17373916
Drug: Rifaximin 1600
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 1600 mg/day
Trial: 16378561
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid gel 1% (one drop, four times daily for one week)
Trial: 16378561
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one drop, four times daily for one week)
Trial: 16378561
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid gel 1%
Trial: 9527749
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anaesthesia with 8 mg of hyperbaric bupivacaine 0.5%
Trial: 9527749
Drug: Combined sciatico‐femoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sciatico‐femoral nerve block with 7 mg kg(‐1) of mepivacaine 2%
Trial: 10150352
Drug: Adhesive-sparing moisturizing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adhesive-sparing moisturizing cream, 0.1 mL applied to gloves
Trial: 10150352
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cream)
Trial: 2673080
Drug: Dried chopped
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried chopped feverfew (70‐86 mg)
Trial: 24105072
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg ethinyl-estradiol (EE) with 3 mg drospirenone
Trial: 24105072
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg ethinyl-estradiol (EE) with 3 mg drospirenone
Trial: 24105072
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (20 μg EE and 30 μg EE)
Trial: 20439553
Drug: Concord grape
RxNorm normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concord grape juice (CGJ) 480 mL daily for 12 weeks
Trial: 20439553
Drug: Substitute grape-flavored
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitute grape-flavored drink (SGD) 480 mL daily for 12 weeks
Trial: 17255252
Drug: NaDCC tablets
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaDCC tablets
Trial: 14999359
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (660 mg daily, 440 mg for patients ≥65 years)
Trial: 14999359
Drug: Acetaminophen (4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4000 mg daily)
Trial: 11682416
Drug: Tramadol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 0.5 mg/kg
Trial: 11682416
Drug: Amitriptyline 15
RxNorm normalized name: amitriptyline 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 15 or 20 mg
Trial: 7948797
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine (0.2 mg/kg) and scopolamine (0.01 mg/kg)
Trial: 7948797
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.75 mg/kg)
Trial: 3283766
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Flutamide and LHRH agonist [D‐Trp]LHRH ethylamide
Trial: 3283766
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Flutamide
Trial: 20820150
Drug: Premedication consisting
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premedication consisting of 7.5 mg midazolam, 50 mg diclofenac, 1000 mg acetaminophen (orally) and fentanyl (intravenously)
Trial: 11817992
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose polyethylene glycol 3350 plus electrolytes (PEG+E)
Trial: 10632776
Drug: finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: finasteride 5 mg daily for 24 months
Trial: 10632776
Drug: placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily for 24 months
Trial: 2019938
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (0.10 mg/kg in 2 ml 0.9% saline solution)
Trial: 2019938
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution placebo
Trial: 6814298
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (IV NTG) 0.5 micrograms/kg/min
Trial: 6814298
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (IV NTG) 0.1 micrograms/kg/min
Trial: 30765737
Drug: DHA-CHO-VE multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-CHO-VE multivitamin treatment (DHA, choline, vitamin E)
Trial: 30765737
Drug: DHA-VD multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-VD multivitamin treatment (DHA, vitamin D)
Trial: 30541606
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg lidocaine + 2 mg CPC
Trial: 30541606
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg lidocaine + 2 mg CPC
Trial: 27026311
Drug: Rectal V38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal V38 (≥2.0 cm³)
Trial: 29499622
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of anticoagulants
Trial: 27026311
Drug: Rectal V38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal V38 < 2.0 cm³ with anticoagulants or V38 ≥ 2.0 cm³ plus 1 other risk factor
Trial: 22272750
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (oral treatment for four weeks)
Trial: 15150185
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g once a day
Trial: 10955752
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled terbutaline (500-1000 microg four times daily)
Trial: 1614781
Drug: Rice, soy-protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice, soy-protein isolate, corn syrup solids, and vegetable oil (group RS)
Trial: 31206571
Drug: Pulpectomy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulpectomy treatment with Maisto‐Capurro paste (G1)
Trial: 31206571
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 3Mix‐MP paste (G2)
Trial: 24520674
Drug: Yuleshu oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuleshu oral mixture combined with conventional therapy
Trial: 17239325
Drug: 5‐hydroxytryptamine type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐hydroxytryptamine type 3 receptor antagonists
Trial: 8286805
Drug: Clindamycin 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 2% vaginal cream
Trial: 7498208
Drug: Prolonged sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged sequential inflations (3 to 5 inflations of 3 to 5 min each, total duration > or = 12 min, group 1, n = 20 lesions)
Trial: 7498208
Drug: Standard sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sequential inflations (3 to 5 inflations of < or = 1 min each, total duration < or = 3 min, group 2, n = 24 lesions)
Trial: 2188696
Drug: Day patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day patient treatment
Trial: 7040497
Drug: Bumetanide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (0.5 mg intravenous)
Trial: 7040497
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg intravenous)
Trial: 28404973
Drug: L-asparaginase, cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase, cisplatin, etoposide, and dexamethasone (LVDP) plus concurrent chemoradiotherapy (CCRT)
Trial: 24339273
Drug: Group Training
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Training (GT) of the Otago Exercise Program (OEP) performed twice weekly for 12 weeks
Trial: 23326865
Drug: Perindopril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (5 mg)
Trial: 23326865
Drug: Perindopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (10 mg)
Trial: 19236441
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection into normal tissue
Trial: 19236441
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection into lipohypertrophic tissue
Trial: 19236441
Drug: Injection sites
RxNorm normalized name: IV SET W/2 INJECTION SITES 15GTTS/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sites (normal vs lipohypertrophic)
Trial: 18444444
Drug: Dronabinol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (10 mg)
Trial: 8053585
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at target blood concentration 2 micrograms/ml
Trial: 8053585
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at target blood concentration 4 micrograms/ml
Trial: 2903191
Drug: Intensified antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified antihypertensive treatment aiming to lower diastolic blood pressure to less than or equal to 80 mmHg.